Traumatic brain injury (TBI) causes significant mortality. Dexmedetomidine (DEX) shows neuroprotective potential in animals, but clinical evidence remains inconsistent. We evaluated the impact of early DEX, initiated within 48 h of admission with a treatment duration of at least 4 h, on survival in intensive care unit (ICU) patients with TBI using the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database. Outcomes included 28-day, hospital, and 1-year mortality, analyzed via propensity score matching (PSM), multivariable Cox models, and subgroup analyses. Of 2378 patients, 241 received DEX. After PSM (235 pairs), early DEX use significantly reduced 28-day (HR 0.45, 95% CI 0.30-0.69, p < 0.001) and hospital mortality (HR 0.25, 95% CI 0.15-0.42, p < 0.001). These results remained robust across sensitivity analyses. Similarly, 1-year mortality decreased (HR 0.64, 95% CI 0.47-0.87, p < 0.01) and further supported by the Boruta algorithm, although inverse probability of treatment weighting analysis showed only a non-significant trend (p = 0.08). Survival benefits were more pronounced in patients aged <65 and those requiring mechanical ventilation. In conclusion, early DEX use is associated with improved short- and long-term survival in ICU patients with TBI, particularly in younger individuals and those requiring mechanical ventilation. Randomized controlled trials are warranted to establish causality.

Obsessive-compulsive disorder (OCD) is a common and disabling, as well as underdiagnosed, neuropsychiatric condition characterized by involuntary and unwanted obsessions and/or compulsions, often accompanied by states of severe anxiety, distress and shame, as well as other comorbid disorders. Despite the extensive literature available to date, only some of the neurobiological mechanisms underlying the symptomatic manifestations of the disorder have been clarified, underlining the need for further research. The brain structures involved are hippocampus, amygdala, striatum, thalamus, dorsolateral prefrontal cortex, anterior cingulate cortex, and orbitofrontal cortex; furthermore, most studies have mainly focused on the expressive modalities and on the individual structural and functional alterations of the brain, generating sometimes conflicting data. The aim of this article is therefore to summarize and bring together the main evidence collected so far on what would appear to be the neuroanatomical correlates and mechanisms underlying the disorder and its manifestations, to provide a sufficiently clear and complete overview.

Cranial-irradiation is associated with tissue damage resulting in neurocognitive impediments that adversely influence patient quality of life. Administration of radiation directly to the tumor may extend to the neighboring healthy tissues, which may induce acute to persistent oxidative stress, lessening neurogenesis, neuroinflammation, as well as vascular alterations, leading to neurocognitive sequelae as a result of decline in neuronal structural complexity as well as synaptic connections. Almost all the medications indicated in the treatment of irradiation-triggered brain injury work via signaling pathways that are associated with lessening chronic oxidative stress, which is considered a consequence of the inflammatory response, reduction of edema, as well as microglia activation. Some agents have both preventative as well as therapeutic potential via the amalgamation of both neuroprotective and therapeutic mechanisms above. Thus, in this review, agents such as baicalein, troxerutin, epigallocatechin gallate, quercetin, melatonin, valproic acid, lithium, neurosteroid progesterone as well as minocycline have been implicated as neuroprotective agents for irradiation-induced neurological deficits. Also, agents such as glucocorticoids, methylphenidate, vitamin E, bisdemethoxycurcumin, phosphodiesterases, edaravone, pioglitazone and fenofibrate, glutamate antagonists, human urinary kallidinogenase, bevacizumab, as well as hyperbaric oxygen have been implicated as therapeutic agents for irradiation-induced neurological deficits. Furthermore, agents such as angiotensin-converting enzyme, 3-N-butyl-phthalide, stem cell therapy, sphingosine-1-phosphate, gangliosides, and neurotrophins have been implicated as combined potential neuroprotective and therapeutic agents for irradiation-induced neurological deficits. The aim of this review is to elucidate the potential neuroprotective and therapeutic agents above and their mechanisms for irradiation-induced neurological deficits after brain irradiation.

Facial expression recognition (FER) has emerged as a pivotal interdisciplinary research domain that bridges computer science, psychology, neuroscience, and medicine. By mapping the FER scientific knowledge graph, this study aimed to explore the technological evolution and forecast future trends in this field. The study collected and cleaned the research on emotion perception in the Web of Science (WoS) database, and utilized the software CiteSpace (version 6.4R1) and R (BiblioShiny packages) software to create a scientific knowledge map. K-means was used for cluster analysis, and then the latent Dirichlet allocation (LDA) was employed to extract popular topics from the text of each cluster. Uniform manifold approximation and projection (UMAP) was utilized to reduce high-dimensional embeddings to a two-dimensional space. From a regional perspective, research is mainly distributed in countries or regions such as North America, Western Europe, East Asia, India, and Australia. Research on facial emotion recognition has focused primarily on neuroscience, psychiatry, and psychology. With the rapid development of computer technology, the interdisciplinary intersection is becoming increasingly important as FER has shown strong potential in identifying rare and neurological diseases. Furthermore, the evolution of artificial intelligence (AI) has transformed facial expression feature extraction from manual methodologies to machine learning-based approaches. The rapid development of computer algorithms and AI has greatly improved the accuracy and speed of facial emotion recognition. As a technology capable of detecting instantaneous emotional changes, FER holds promising prospects in fields such as neuroscience, emotion analysis, and pain assessment.

In psychopathology, one of the most complex challenges is offered by the diagnostic comparison between patients with borderline personality disorder and those with bipolar spectrum disorder, as some of the symptoms characterizing the two disorders overlap. This detail can mislead therapists who are often called upon to diagnose these syndromes, and in some cases, there is a tendency to diagnose both as one is a personality disorder and the other is a mood disorder. This article provides the reader with a complete overview of these two disorders, highlighting some aspects that could redefine their clinical framework. This need could favor a reduction in cases of diagnostic error, also through the proposal of an innovative psychometric tool, Perrotta Border‐Bipolar Profile Diagnostic Questionnaire, currently being validated.

Several noninvasive brain stimulation techniques have gained significant attention in neurocognitive science and clinical research due to their potential efficacy in addressing neurological, psychiatric, and cognitive impairments. This study explores global trends and research hotspots in brain stimulation research for cognitive impairment and related disorders. Using a data set from 1989 to 2024 sourced from the Web of Science Core Collection, 4156 records were analyzed through bibliometric methods, including publication trends, country or region, and institutional analysis, and document co-citation analysis (DCA). Results revealed a steady increase in research, with a significant increase in publications during the period from 2019 to 2023. The USA led in citation counts (1117), centrality (0.37), while China topped the burst value (72.31). The University of London led in citation counts (235), whereas Capital Medical University topped the sigma value (1.77). Transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS) dominated the top positions in DCA analysis. Emerging trends were identified through burst keywords, including "transcranial Doppler," "subthalamic nucleus stimulation," "cerebral blood flow," "vascular dementia," and "cardiopulmonary bypass." These emerging research hotspots underscore the growing focus on vascular aspects of cognitive impairment and advanced brain stimulation methods. Additionally, newer noninvasive techniques like fast gamma magnetic stimulation, paired-associative stimulation with TMS (PAS-TMS), and theta-burst stimulation are identified as promising avenues for future research, offering significant potential for therapeutic advancements. This study provides a comprehensive overview of the global landscape, trends, and future directions in brain stimulation research for cognitive impairment.

Parkinson's disease (PD) is a neurodegenerative disease characterized by degeneration of dopamine neurons in the substantia nigra pars compacta. The patient exhibits a series of motor symptoms, such as static tremors, which impair their capacity to take care for themselves in daily life. In the late stage, the patient is unable to walk independently and is bedridden for an extended period of time, reducing their quality of life significantly. So far, treatment methods for PD mainly include drug therapy and deep brain stimulation. Pharmacotherapy is aimed at increasing dopamine (DA) levels; however, the treatment effect is more pronounced in the short term, and there is no benefit in improvement in the overall progression of the disease. In recent years, novel therapeutic strategies have been developed, such as cell reprogramming, trying to generate more DA in PD treatment. This review mainly discusses the advantages, methodology, cell origin, transformation efficiency, and practical application shortcomings of cell reprogramming therapy in PD strategy.

Parkinson's disease (PD) is a common degenerative disease of the central nervous system that is characterized by movement disorders and non‐motor symptoms (NMSs). The associated NMSs primarily include neuropsychiatric symptoms, autonomic dysfunction, sleep‐wake disorders, pain, fatigue, and hyposmia. These NMSs can occur at any stage of PD, especially before the onset of motor symptoms, and may affect a patient's quality of life more than motor symptoms. Although PD is most commonly diagnosed in people over 65 years, some patients exhibit symptom onset before the age of 50, which is clinically known as early‐onset Parkinson's disease (EOPD). The high heterogeneity and incidence of EOPD‐associated NMSs can lead to the misdiagnosis of EOPD as other neurodegenerative diseases. In this review, we discuss the research progress related to NMSs in patients with EOPD, focusing on neuropsychiatric disorders, autonomic dysfunction, sleep disorders, and sensory impairment, and outline the association of NMSs with different genotypic alterations, with the aim of providing assistance in the clinical management of patients.